TIDMAGL

RNS Number : 7313L

Angle PLC

05 January 2023

 
 For immediate release   05 January 2023 
 

ANGLE plc ("the Company")

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Experienced life science executive, Juliet Thompson, joins ANGLE Board with immediate effect

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that Juliet Thompson has been appointed as a Non-Executive Director of the Company, with effect from 5 January 2023.

Juliet has spent much of her career advising companies in the international life sciences sector, completing multiple financing and M&A transactions in Europe and the United States, helping companies raise in excess of US $4 billion to pursue their growth strategies. Juliet has held senior positions at WestLB Panmure and Stifel Europe and in 2003 was a co-founder of the specialist life science investment bank, Code Securities, later acquired by Nomura.

Juliet currently has a number of roles, including Non-Executive Board positions at Indivior plc, Novacyt SA and the private company, OrganOx. She chairs the Audit Committees of all three companies and is a member of the remuneration and nomination committees.

Juliet Thompson, commented:

"As a founder of two businesses and with a long track record advising companies, I understand the challenges faced by executive management teams of growth companies. I have specialist knowledge in the areas of financing, strategy and corporate governance and I look forward to bringing this experience to ANGLE as the Company looks to further advance its world leading position in CTC liquid biopsy."

ANGLE Chairman, Garth Selvey, added:

"I am delighted that Juliet has agreed to join the Board of ANGLE at such an exciting time in our commercial development. Juliet has extensive experience in the life science sector and will strengthen the Board with her entrepreneurial expertise and deep knowledge of capital markets."

Other than as disclosed below, there are no further disclosures to be made in connection with Juliet Thompson (age 56) in accordance with AIM Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies:

 
 Current                                 Previous 
 Indivior plc                            Vectura Group Limited 
                                        ---------------------- 
 Novacyt SA                              GI Dynamics, Inc. 
                                        ---------------------- 
 OrganOx Limited                         Nexstim Oyj 
                                        ---------------------- 
 Opus Trust Investments Limited          Scapa Group Limited 
                                        ---------------------- 
 Opus 107 Limited                        Premier Vet Group plc 
                                        ---------------------- 
 Leadership Through Sport and Business 
                                        ---------------------- 
 

For further information:

 
 ANGLE plc                                        +44 (0) 1483 343434 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
  Andrew Holder, Head of Investor Relations 
 Berenberg (NOMAD and Joint Broker) 
  Toby Flaux, Ciaran Walsh, Milo Bonser           +44 (0) 20 3207 7800 
 
   Jefferies (Joint Broker) 
   Max Jones, Thomas Bective                        +44 (0) 20 7029 8000 
 
   FTI Consulting 
   Simon Conway, Ciara Martin                       +44 (0) 203 727 1000 
   Matthew Ventimiglia (US)                         +1 (212) 850 5624 
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) . Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected circulating tumor cell (CTC) harvesting technology is known as the Parsortix(R) system.

ANGLE's Parsortix(R) system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical device to harvest intact circulating cancer cells from blood.

Intended use

The Parsortix(R) PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K(2) EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

The Parsortix system enables a liquid biopsy (a simple blood test) to be used to provide the circulating metastatic breast cancer cells to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as well as CTC clusters in a viable form (alive). CTCs harvested from the system enable a complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis as well as cytological and morphological examination and may provide comparable analysis to a tissue biopsy in metastatic breast cancer. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.

In the United States, the Parsortix(R) PC1 system has received a Class II Classification from FDA for use with metastatic breast cancer patients. FDA clearance is seen as the global gold standard. ANGLE's Parsortix system is the first ever FDA cleared system for harvesting CTCs for subsequent analysis. ANGLE has applied the IVD CE Mark to the same system for the same intended use in Europe.

ANGLE has also completed three separate 200 subject clinical studies under a programme designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.4% with sensitivity of 90% and specificity of 93%. This excellent clinical result demonstrates the utility of cells harvested by the Parsortix system, which the Company believes is the "best sample" for liquid biopsy analysis as it recovers intact, living cancer cells that are involved in the progression of the disease providing prospective information.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 76 peer-reviewed publications and numerous publicly available posters from 33 independent cancer centres, available on our website.

ANGLE has established clinical services laboratories in the UK and the United States to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services globally to pharmaceutical and biotech customers for use of Parsortix in cancer drug trials and, once the laboratories are accredited and tests validated, will provide Laboratory Developed Tests (LDTs) for patient management.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADDGDBUDGDGXS

(END) Dow Jones Newswires

January 05, 2023 02:01 ET (07:01 GMT)

Angle (LSE:AGL)
Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more Angle Charts.
Angle (LSE:AGL)
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more Angle Charts.